Klieser E, Strauss W H, Lemmer W
Rheinische Landes-und Hochschulklinik Düsseldorf, Germany.
Acta Psychiatr Scand Suppl. 1994;380:68-73. doi: 10.1111/j.1600-0447.1994.tb05836.x.
Remoxipride and clozapine are new neuroleptics that are thought to be superior to the substances in use by their efficacy and tolerance. At the University Clinic of Psychiatry in Düsseldorf a double-blind study with 54 patients diagnosed as schizophrenic in accordance with DSM-III was conducted to record the influence of the neuroleptics remoxipride, clozapine and haloperidol on schizophrenic psychosis. The schizophrenic symptoms were rated by the AMDP-system (Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie), Brief Psychiatric Rating Scale and the Clinical Global Impression on days 0, 7, 14, 21 and 28 of treatment to evaluate the degree of change in psychopathology. The tolerance of the neuroleptic treatment was checked by the doctor's overall impression and the somatic findings of the AMDP-system. All 3 neuroleptics reduced the schizophrenic symptoms to a similar degree but showed differentiation as to their side effects.
瑞莫必利和氯氮平是新型抗精神病药物，人们认为它们在疗效和耐受性方面优于正在使用的药物。在杜塞尔多夫大学精神病学诊所，对54名根据《精神疾病诊断与统计手册》第三版诊断为精神分裂症的患者进行了一项双盲研究，以记录抗精神病药物瑞莫必利、氯氮平和氟哌啶醇对精神分裂症性精神病的影响。在治疗的第0、7、14、21和28天，采用AMDP系统（精神病学方法与文献工作小组）、简明精神病评定量表和临床总体印象对精神分裂症症状进行评分，以评估精神病理学的变化程度。通过医生的总体印象和AMDP系统的躯体检查结果来检查抗精神病药物治疗的耐受性。所有三种抗精神病药物都能在相似程度上减轻精神分裂症症状，但在副作用方面存在差异。
